Astra Ab

Astrazeneca Ab

Astra Aktiebolag

Ab Astra

Astra Lakemedel Aktiebolag

Aktiebolaget Astra

Astra Lakemedel Ab

Hammercap Ab

Arne T Eek

Billy Nilson

Lars-Inge Olsson

Sven Erik Sj Ostrand

Axel B Persson

Bo I Borg

Per Lennart Lindberg

Nils B Nilson

Magnus Bolmsj&ouml;

Rolf Bergman

Nils-Ake W Ternerot

Sven E Sjostrand

Erwan Arzel

Johan Raud

Anders T Kers

Lars-Erik Andersson

The present invention relates to novel boron comprising compounds, to pharmaceutical compositions comprising said compounds, to the therapeutic use of said compounds, and to a process for preparation of said compounds. The compounds are useful in boron neutron capture therapy (BNCT). 

Boron compounds useful in BNCT

The present invention relates to novel compounds of Formula I, and pharmaceutically acceptable salts thereof, as antibacterial agents. The compounds of the present invention are nitric oxide releasing derivatives of proton pump inhibitors (NO-releasing PPIs). In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least one compound of the invention, or a pharmaceutically acceptable salt thereof, as active ingredient; and to the use of the active compounds in the manufacture of medicaments for the medical use indicated above. The invention also relates to new intermediates for use in the preparation of the novel compounds. Additionally the present invention relates to co-administration of NO-releasing PPIs with other known medicaments.

Compounds useful as antibacterial agents

Use of compounds as antibacterial agents

Medical device ( ) for effecting heat treatment and local delivery of a fluid medicament on body tissue presenting a predetermined section of a boundary wall of a passageway in a human or animal body comprising a catheter-like member ( ) for insertion into the passageway to a predetermined insertion position, the catheter-like member being provided with an inflatable balloon structure ( ) having a boundary wall which is inflatable against the body tissue when the catheter-like member ( ) is in the predetermined insertion position and delivery means ( ) for local delivery of the fluid medicament on the body tissue when the catheter-like member ( ) is in the predetermined insertion position, and a heating arrangement ( ) which is adapted to heat the body tissue when the catheter-like member ( ) is in the predetermined insertion position. The delivery means ( ) comprises a supply channel ( ) for supply of the fluid medicament to the balloon structure ( ) and a construction for the boundary wall ( ) of the balloon structure ( ) which is permeable to the fluid medicament. Supply of the fluid medicament to the balloon structure along the supply channel ( ) when the catheter-like member ( ) is in the predetermined insertion position thereby causes the balloon structure ( ) to inflate and fluid medicament to be delivered locally on the body tissue through the boundary wall ( ) of the balloon structure ( ).

Medical device for internal heat treatment and drug delivery

A delivery means for delivering liquid containing medicament to a posterior region of the nasal cavity, comprising an elongate tubular member (,) and a nozzle (,) at the free end thereof, which nozzle (,) includes at least one opening (,) through which liquid is in use delivered.

Device for delivering liquid containing medicament

Pump chamber and valve for a pump chamber

Combination of a .beta.-receptor blocker and an opioid

Combination of a .beta.-receptor blocker and a local anaesthetic

Use of a pharmaceutically acceptable salt of ropivacaine for the manufacture of a pharmaceutical preparation with sensoric block and minimal motor blockade.

Methods and compositions for the treatment of pain utilizing ropivacaine

Infusion bag

A synergistic pharmaceutical combination or composition is disclosed for the treatment of gastritis and peptic ulcer containing a therapeutic amount of a histamine H.sub.2 receptor blocking agent, which increases intragastric pH, and an acid degradable antibacterial compound. In particular, the combination is directed to the treatment of infections by Helicobacter pylori by raising the bioavailability of acid degradable antibacterial compounds.

Synergistic combination of a substance with gastric acid secretion

A synergistic pharmaceutical combination and composition are disclosed for the treatment of gastritis and peptic ulcer containing a therapeutic amount of a proton pump inhibitor such as e.g., omeprazole or lansoprazole, which increases intragastric pH, and a therapeutic amount of an acid degradable antibacterial compound such as a penicillin or a macrolide. In particular, the combination is directed to the treatment of infections caused by Helicobacter pylori by raising the bioavailability of acid degradable antibacterial compounds.

The invention consists of a combination of a substance that increases the intragastric pH and an acid degradable antibacterial compound. By this combined product regimen it will be possible to obtain maximal local antibacterial effect of acid degradable antibiotics as well as enhanced bioavailability of the active antibiotic, thus resulting in higher amounts of the active compound in the gastric mucosa due to secretion of weak bases. Both pharmacological effects contribute to drastically increased antimicrobial capacity of acid degradable antibiotics to be used against local infections in the gastrointestinal tract causing gastritis and/or peptic ulcer. The invention also selects to the use of said combination and a process for the preparation thereof.

Transfer cannula

Growing community of inventors

Trosa, Sweden

Arne T Eek